Sanaria competitors

Ryan Spencer is a Board Member at Dynavax Technologies and Chief Executive Officer at Dynavax Technologies and is based in Berkeley, California. He has worked as Senior Director Commercial Operations at Dynavax Technologies; Senior Product Director, HEPLISAV-B at Dynavax Technologies; and Vice President, Corporate Strategy & Commercial Operations at Dynavax Technologies. Ryan attended Universidade Federal de Santa Catarina between 1995 and 1999.

Richard Maradie is a Chief Executive Officer at NOVAVAX INC and is based in Rockville, Maryland.

Steve Brugger brings over 30 years of experience in the biotech and pharmaceutical industry to Affinivax. He most recently served as the Chief Executive Officer of Visterra, a private biotech company based in Cambridge, Mass. During his tenure at Visterra, Steve led the company in closing a Series A round of financing, advancing its lead antibody program toward IND, and establishing strategic partnerships with both Pfizer and the Bill & Melinda Gates Foundation. Prior to Visterra, Steve was the Chief Operating Officer at Momenta Pharmaceuticals. While at Momenta, Steve held several leadership roles as the company grew from a private start-up to a successful public-traded biotechnology company. Prior to Momenta, Steve held various leadership and management positions at Millennium, Novartis, Ayerst, and Hoechst Pharmaceuticals. Steve received his BA in Biology from Susquehanna University and his MBA from the Rutgers Graduate School of Management.

Recognized leader with highly successful experience and expertise in transforming and restructuring public and private companies, establishing strong governance processes and operational discipline, resulting in operational improvements, significant revenue and enterprise value growth. During his career, Mr. Dodd has overseen the approval of over 10 NDAs, over 15 acquisitions/divestitures, in excess of $2.5 billion in financial transactions and, over $5 billion in incremental enterprise growth. expertise in General Management; Board Leadership; Community & Industry Leadership.Specialties: General Management & Board Leadership Life Sciences IndustryBusiness TransformationsM&A

Michael Reilly is a biotechnology commercialization professional working with emerging biotechnology companies, venture capital, and private equity firms on commercialization and business development. His focus is on shaping and maximizing the future value of medicines for patients and investors through thoughtful choices in the product development process. Michael has over 20 years of leadership experience in pharmaceuticals, devices, diganostics, and industrial biotechnology. His direct experience in developing and commercializing drugs spans pre-IND stage, clinical, launch, and patent expiration.